MeSH term
Frequency | Condition_Probility | Animals | 23 | 0.0 |
Cell Division | 4 | 0.0 |
Homeodomain Proteins/*genetics | 9 | 2.0 |
Humans | 67 | 0.0 |
Mice | 9 | 0.0 |
Mice, Inbred C57BL | 3 | 0.0 |
Nuclear Pore Complex Proteins/*genetics | 10 | 66.0 |
Research Support, Non-U.S. Gov't | 46 | 0.0 |
Retroviridae/genetics | 4 | 1.0 |
Acute Disease | 9 | 0.0 |
Amino Acid Sequence | 23 | 0.0 |
Base Sequence | 15 | 0.0 |
Chromosomes, Human, Pair 11/genetics | 5 | 2.0 |
Chromosomes, Human, Pair 7/genetics | 2 | 2.0 |
Leukemia, Myeloid/*genetics | 5 | 3.0 |
Molecular Sequence Data | 28 | 0.0 |
Neoplasm Proteins/genetics | 5 | 1.0 |
Oncogene Proteins, Fusion/genetics | 2 | 2.0 |
Translocation, Genetic/*genetics | 10 | 4.0 |
Amino Acid Motifs | 3 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Cell Transformation, Neoplastic/*genetics | 3 | 1.0 |
Comparative Study | 4 | 0.0 |
Oncogene Proteins, Fusion/genetics/*physiology | 2 | 11.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 25 | 0.0 |
Translocation, Genetic | 7 | 0.0 |
Aged | 3 | 0.0 |
Carrier Proteins/*genetics | 2 | 0.0 |
Chromosomes, Human, Pair 11 | 3 | 0.0 |
Chromosomes, Human, Pair 8 | 2 | 1.0 |
In Situ Hybridization, Fluorescence | 5 | 0.0 |
Male | 21 | 0.0 |
Nuclear Proteins/*genetics | 10 | 1.0 |
Oncogene Proteins, Fusion/*genetics | 9 | 4.0 |
RNA, Neoplasm/analysis | 2 | 0.0 |
*Translocation, Genetic | 17 | 1.0 |
Base Sequence/genetics | 2 | 0.0 |
Female | 15 | 0.0 |
Middle Aged | 13 | 0.0 |
Binding Sites | 6 | 0.0 |
Cells, Cultured | 2 | 0.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Glycine/chemistry | 2 | 6.0 |
Green Fluorescent Proteins | 6 | 0.0 |
Hela Cells | 15 | 0.0 |
Luminescent Proteins/metabolism | 6 | 1.0 |
Microscopy, Fluorescence | 3 | 0.0 |
Protein Binding | 7 | 0.0 |
Time Factors | 2 | 0.0 |
*Transcription, Genetic | 4 | 0.0 |
Transfection | 5 | 0.0 |
Xenopus | 6 | 1.0 |
Blotting, Southern | 4 | 0.0 |
Homeodomain Proteins/genetics | 3 | 1.0 |
Leukemia, Myelocytic, Acute/*genetics | 7 | 6.0 |
Reverse Transcriptase Polymerase Chain Reaction | 13 | 0.0 |
Active Transport, Cell Nucleus | 7 | 2.0 |
Cell Line | 6 | 0.0 |
Immunohistochemistry | 2 | 0.0 |
Nuclear Pore Complex Proteins/*metabolism | 2 | 15.0 |
Nuclear Proteins/*metabolism | 2 | 0.0 |
Rats | 5 | 0.0 |
Recombinant Fusion Proteins/metabolism | 4 | 0.0 |
Chromosome Breakage/genetics | 3 | 4.0 |
Antineoplastic Agents/pharmacology | 2 | 0.0 |
Cell Transformation, Neoplastic/genetics | 5 | 1.0 |
Models, Genetic | 2 | 0.0 |
Protein Structure, Tertiary | 8 | 0.0 |
Cell Nucleus/*metabolism | 7 | 1.0 |
Cytoplasm/metabolism | 3 | 0.0 |
DNA, Complementary | 2 | 0.0 |
DNA-Binding Proteins/genetics/metabolism | 3 | 0.0 |
Nuclear Pore/metabolism | 3 | 27.0 |
Tumor Cells, Cultured | 3 | 0.0 |
Adolescent | 7 | 0.0 |
*Chromosomes, Human, Pair 11 | 16 | 2.0 |
*Chromosomes, Human, Pair 2 | 3 | 1.0 |
DNA, Neoplasm/genetics | 2 | 0.0 |
Gene Expression Regulation, Leukemic | 3 | 3.0 |
Gene Fusion | 7 | 7.0 |
Homeodomain Proteins/biosynthesis/*genetics | 2 | 9.0 |
Leukemia, Myelomonocytic, Acute/*genetics | 2 | 8.0 |
RNA, Messenger/genetics | 4 | 0.0 |
RNA, Messenger/*metabolism | 3 | 0.0 |
Sequence Homology, Amino Acid | 8 | 0.0 |
Models, Biological | 5 | 0.0 |
Karyotyping | 8 | 0.0 |
Child | 5 | 0.0 |
*Intracellular Signaling Peptides and Proteins | 2 | 0.0 |
Membrane Proteins/*genetics | 9 | 1.0 |
*Nuclear Pore Complex Proteins | 22 | 31.0 |
Cell Nucleus/metabolism | 3 | 0.0 |
Nuclear Pore Complex Proteins/genetics/*metabolism | 2 | 40.0 |
Biological Transport | 4 | 0.0 |
Gene Targeting | 2 | 0.0 |
Nuclear Pore/*metabolism | 3 | 27.0 |
*Receptors, Cytoplasmic and Nuclear | 2 | 2.0 |
Gene Products, rev/*metabolism | 3 | 30.0 |
Microscopy, Immunoelectron | 5 | 0.0 |
Mutation | 3 | 0.0 |
Bone Marrow Transplantation | 2 | 0.0 |
Transduction, Genetic | 3 | 0.0 |
Membrane Proteins/metabolism | 2 | 0.0 |
*Nucleocytoplasmic Transport Proteins | 2 | 5.0 |
Sequence Alignment | 2 | 0.0 |
Two-Hybrid System Techniques | 2 | 0.0 |
Membrane Proteins/genetics | 2 | 0.0 |
Nuclear Proteins/genetics | 3 | 1.0 |
Child, Preschool | 2 | 0.0 |
Chromosomes, Human, Pair 11/*genetics | 8 | 3.0 |
Chromosomes, Human, Pair 20/*genetics | 2 | 3.0 |
Cloning, Molecular | 7 | 0.0 |
*Chromosomes, Human, Pair 7 | 4 | 1.0 |
Immunophenotyping | 3 | 0.0 |
*Transcription Factors | 2 | 0.0 |
Adult | 6 | 0.0 |
*Chromosomes, Human, Pair 4 | 2 | 0.0 |
Karyopherins | 3 | 10.0 |
Plasmids/metabolism | 3 | 0.0 |
Recombinant Proteins/metabolism | 2 | 0.0 |
RNA Interference | 2 | 0.0 |
Chromosomes, Human, Pair 7/*genetics | 2 | 1.0 |
Fatal Outcome | 3 | 0.0 |
Genes, Homeobox/genetics | 2 | 6.0 |
Hematopoiesis/genetics | 2 | 5.0 |
Cell Division/genetics | 2 | 0.0 |
Chromosome Mapping | 5 | 0.0 |
Chromosomes, Artificial, Yeast | 2 | 0.0 |
Cosmids | 2 | 0.0 |
*Exons | 2 | 0.0 |
Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Introns | 2 | 0.0 |
*Membrane Proteins | 2 | 0.0 |
Neoplasm Proteins/*genetics | 4 | 0.0 |
Polymerase Chain Reaction | 3 | 0.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
Rhabdoid Tumor/genetics | 2 | 66.0 |
Rhabdomyosarcoma/genetics | 2 | 15.0 |
Transcription, Genetic | 5 | 0.0 |
Myelodysplastic Syndromes/chemically induced/*genetics | 2 | 100.0 |
Chromosomes, Human, Pair 11/*genetics/ultrastructure | 2 | 11.0 |
Protein Conformation | 2 | 0.0 |
Neoplasms, Second Primary/*genetics | 2 | 9.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Dimerization | 2 | 0.0 |
Trans-Activation (Genetics) | 3 | 0.0 |
Cell Nucleolus/metabolism | 2 | 5.0 |
Dactinomycin/pharmacology | 2 | 0.0 |
*Gene Rearrangement | 2 | 0.0 |
Macromolecular Substances | 2 | 0.0 |
Models, Molecular | 2 | 0.0 |
Nuclear Proteins/biosynthesis/*chemistry/*metabolism | 2 | 66.0 |
DNA, Complementary/genetics | 3 | 0.0 |
Sequence Analysis, DNA | 3 | 0.0 |
beta Karyopherins | 2 | 13.0 |
RNA, Neoplasm/genetics | 2 | 0.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Blotting, Western | 2 | 0.0 |
Flow Cytometry | 2 | 0.0 |
K562 Cells | 2 | 0.0 |
COS Cells | 2 | 0.0 |
DNA Primers/chemistry | 2 | 0.0 |
DNA Topoisomerases, Type I/*genetics | 2 | 12.0 |
